Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical TechnologyMSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan's BLA to treat ES-SCLC.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC. RegulatoryOncologyRead full story Post navigation Previous: Alamar, Hemab, Kailera, and Seaport advance IPOsNext: Revolution rockets on strong pancreatic cancer data Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
